Kornimate/medical-research-clean huggingface dataset:
non-interventional retrospective multicenter study of patients with bronchial asthma during a routine visit to out of patients' clinics

Conditions: Asthma

Summary: to assess asthma control in russian patients according to the new criteria provided in the international guidelines and identify pharmacological approaches that provide a higher level of overall asthma control


Eligibility criteria:
inclusion criteria: * male and female patients over 18 years of age * patients with asthma diagnosed in accordance with the global initiative for asthma (gina \[xv\]) within 6 months before inclusion into the study. patients with no changes in their treatment within 2 months before inclusion into the study * patients who signed their informed consents to collection and further processing of data on their disease course exclusion criteria: * asthma patients with an exacerbation at the moment of inclusion. * patients on β-blockers. * patients with copd, mucoviscidosis or bronchiectasis, severe heart failure (nyha functional class iii-iv), renal insufficiency, cancer, previous stroke. * pregnant women. * patients following a major surgery, hepatic insufficiency.

Keywords: asthma asthma in children
study of vir-2218 with or without pegylated interferon alpha-2a for treatment of chronic hepatitis b virus infection

Conditions: Chronic Hepatitis B

Summary: this is a phase 2 study in which subjects with chronic hepatitis b virus (hbv) infection will receive vir-2218 alone or in combination with pegylated interferon alfa-2a and will be assessed for safety, tolerability, pharmacokinetics, and antiviral activity.


Eligibility criteria:
inclusion criteria: * male or female of ages 18 - 65 * chronic hbv infection for \>/= 6 months exclusion criteria: * any clinically significant chronic or acute medical condition that makes the volunteer unsuitable for participation * significant fibrosis or cirrhosis * history or evidence of drug or alcohol abuse * history of intolerance to sc injection * history of chronic liver disease from any cause other than chronic hbv infection * history of hepatic decompensation * any prior receipt of an interferon product

Keywords: hepatitis b virus chronic hepatitis b hbv hepatitis
grasping rehabilitation using motor imagery with or with no neurofeedback after tetraplegia

Conditions: Individuals With C6-C7 Tetraplegia (AIS A or B)

Summary: motor imagery has shown promising results to optimize tenodesis grasp in individuals with c6-c7 tetraplegia. however, efficacy of using motor imagery to improve grasping after tetraplegia requires further study with higher level of evidence. in addition, controlling covert practice remains difficult due to the absence of overt movements. however, similar brain activity measured during both over and cover movements makes possible to provide visual information about the covert practice performance using neurofeedback. the investigators thus designed this multicentric randomized controlled trial to investigate the effect of motor imagery with or with no visual neurofeedback on grasping capabilities after c6-c7 tetraplegia. they hypothesized that providing neurofeedback based on brain activity measured by electroencephalography namely knowing the covert practice performance would results in greater grasping improvement in response to practice as compared to motor imagery practice alone.


Eligibility criteria:
inclusion criteria: * volunteer individuals with c6-c7 tetraplegia with complete finger flexor paralysis restricting grasping capabilities to the tenodesis. * consent to participate to the study after receiving clear, loyal and appropriate information. * aged between 18 and 55 years. * time since spinal cord injury above 6 months * stabilized condition in particular sensori-motor deficit. * sitting position for more than 1 hour * able to imagine movement * health care beneficiary exclusion criteria: * long-lasting autonomic disorders while sitting (orthostatic hypotension and/or blood pressure instability) limiting sitting position to less than 1 hour. * upper limb pain for either mechanic or neuropathic reasons preventing all grasping movement and/or the ability to imagine those movements. * restricted wrist and finger range of motion preventing the tenodesis grasp. * patient after surgical tendon transfer that improved grasping capabilities (e.g. active finger flexion). * ongoing participation in another research that aim to evaluate an intervention likely to improve the neurological or functional recovery introducing an experimental bias. * specific contraindication to magnetoencephalography with the presence of metallic fragments inside the body such as pace-maker, neurostimulator, cochlear implants, steel dental implant and osteosynthesis material only applicable to the participants included in lyon hospital center (n=15).

Keywords: tenodesis grasp neurofeedback motor imagery reach-to-grasp rehabilitation physical therapy cervical spinal cord injury tetraplegia ais a ais b
effects of alpha lipoic acid supplementation in g6pd deficient individuals after acute exercise

Conditions: G6PD Deficiency

Summary: the purpose of this study is to investigate the effects of alpha-lipoic acid supplementation on redox status, physiological and biochemical parameters in g6pd deficient individuals after acute exercise.

in a randomized double-blind, crossover design, 12 adult volunteers with g6pd deficiency of both sexes will be supplemented with either 600 mg of alpha-lipoic acid (experimental condition - ec) or placebo (control condition - cc) every day for 4 weeks. before intervention, all participants will be informed about the study protocol, fill a medical history questionnaire and sign an informed consent form. moreover, measurements of anthropometric characteristics and physiological parameters, as well as a vo2max test will be performed. participants will perform 4 trials of exercise (70% vo2max for 45min and 90% till exhaustion) before and after each condition. blood samples will be collected before, immediately after and 1 hour after exercise. moreover, measurements of anthropometric characteristics and physiological parameters will be performed before and after each condition. there will be a washout period of at 4 weeks between conditions.

Eligibility criteria:
inclusion criteria: * g6pd deficiency exclusion criteria: * any uncontrolled health condition for which exercise is contraindicated * current use of dietary supplements or drugs * pregnant, pregnancy intention or breast feeding
a dose-finding, efficacy and safety study of yy-351 in patients with type 2 diabetes

Conditions: Diabetes

Summary: the purpose of this trial is to determine the dosage selected and to evaluate the efficacy and safety of yy-351.

ginseng has been widely studied for treatment of diabetes, dyslipidemia and obesity. interestingly, in addition to ginseng root, ginseng berry and leaf were also shown to reduce blood glucose in diabetic models. in our recent study, ginsam, vinegar extraction from panax ginseng, which is enriched in the ginsenoside rg3, has distinct beneficial effects on glucose metabolism and body weight control in an obese animal model of insulin resistance by changing the expression of genes involved in glucose and fatty acid metabolism. our group has also published that rg3 improves insulin signaling and glucose uptake primarily by stimulating the expression of irs-1 and glut4. thus, we have evaluated the efficacy, dose-response relationships and safety of a ginsam, a vinegar extract from panax ginseng.

Eligibility criteria:
inclusion criteria: * previous diagnosis of type 2 diabetes(more than 3months) * patients aged over 18 years * fpg levels in the range : 126 - 270mg/dl or hba1c : 7.0 - 12.0% exclusion criteria: * pregnant women, breast feeding, or actively trying to be come pregnant * patients with type 1 dm, gestational diabetes or secondary diabetes * fpg levels in the range : ≥ 270mg/dl hba1c : \ 12.0% * patient who take the medicine which may affect to blood sugar control (i.e.systemic glucocorticoid) * patients with diabetic complications or the history of a case that would affect to efficacy and safety evaluation (i.e. thyroid disorder, cushing's syndrome, multiple ovarian cystoma, pheochromocytoma) * patients with chronic hepatitis, hepatitis b, c (except healthy hbv carrier) or liver diseases (ast or/and alt \>2 × uln(upper limit normal)) * patients with kidney disorder (cr\>2.0)

Keywords: diabetes
a study to gain information how well dexpanthenol derma cream helps the face skin to recover after cosmetic lasering

Conditions: Erythema; Skin Recovery

Summary: in this study, researchers want to learn more about the effect of dexpanthenol cream on skin recovery and reduction of skin rash after a dermatological procedure (ablative laser) on the face for treatment of fine wrinkles, scars and open pores in adult women. after the dermatological procedure, participants will return within 3 weeks for 4 visits to the study center to investigate the skin conditions such as redness, irritation, softness and possible side effects. in addition, study participants will be asked about their general acceptance of dexpanthenol cream.

the primary objective is to evaluate the efficacy of the test product to aid skin recovery and reduction of erythema after ablative lasering on the face. secondary objectives comprise clinical efficacy with respect to skin hydration, softness, vitality, appearance etc. and skin recovery, consumer judgement of product performance and acceptability, and safety.

Eligibility criteria:
inclusion criteria: * phototypes i or ii according to the fitzpatrick scale * participants willing to perform the dermatological procedure (ablative laser) on the face for treatment of fine wrinkles, scars and open pores, rosacea * normal eye examination exclusion criteria: * cutaneous pathologies and/or injuries as psoriasis, sensible skin, cancer of the skin, rosacea, atopic dermatitis or other medical criteria to be considered at the moment of the evaluation; * hyperpigmentation and cutaneous marks in the test area that intervenes with the evaluation of possible reactions * active cutaneous pathologies and/or injuries (local and/or disseminated) in the evaluation area * aesthetic or dermatological treatment in the area of evaluation up to 04 weeks before the selection * people with entropy, ectropion, stye, conjunctivitis, uveitis or other active eye diseases * people with corneal ulcerations, blepharitis, meibomitis, pterygium, trichiasis, distichiasis or other eye diseases of moderate or serious intensity

Keywords: skin cream ablative lasering skin hydration consumer satisfaction sensorial perception
registry of thiola ec therapy

Conditions: Cystinuria

Summary: thiola ec represents several modifications of thiola that promise better, more efficacious therapy of cystinuria. first, pill size has changed from 100 mg to 300 mg, meaning that typical pill burden will be reduced from, on average, 10 pills per day to 3-5 pills per day. this change will be welcomed by patients whose fluid intake and administration of potassium citrate are daily impositions. second, the preparation is now enteric-coated, formulated to offer delayed release of active tiopronin. lastly, thiola ec can be taken with food which is an improvement to the inconvenient dosing regimen of thiola, which can only be taken one hour before, or two hours after meals. these changes may affect compliance and side effect profiles compared to those of thiola. in combination with potassium citrate or other alkali preparations, adverse gi effects are relatively common in actively-treated patients with cystinuria. it is possible that gi side effects may be reduced by thiola ec.


Eligibility criteria:
inclusion criteria: 1. 18 years of age or older 2. patients with cystinuria and a history of kidney stones 3. taking thiola ec 4. willing and able to provide consent exclusion criteria: 1. unable to sign informed consent.
accessible weight loss for adults with low vision: a feasibility study

Conditions: Overweight and Obesity

Summary: this study will examine the feasibility of an all-remote approach to enrollment in and implementation of an 8-week weight loss program for adults with low vision. the weight loss program will provide asynchronous support (information, automated texting feedback, tailored emails) for adopting and maintaining lifestyle-based strategies for safe and effective weight loss.


Eligibility criteria:
inclusion criteria: * age ≥18 * english speaking * bmi ≥ 25 and weight \< 300lbs (weight limit due to scale limitations) * legally blind * have an email for personal use and ability to check and respond to email daily * have a smart phone with texting for personal use * sufficient internet plan for daily email checking * sufficient phone plan for 12 or more texts per week * ability to send and receive emails and text messages * ability to join a zoom call on a personal phone, tablet, or computer * ability to complete qualtrics surveys * willing to lose weight through recommended dietary changes, weight tracking and physical activity * interest in one of the specific dietary strategies supported by the text messaging platform * willing to use the study scale with cellular technology to report weights * willing to join an 8-week weight loss program and interested in losing weight * completion of screening, enrollment and baseline data collection exclusion criteria: * lost 5% of body weight in the last 6 months * currently participating in a weight loss program or another weight loss study * previously diagnosed eating disorder, or treatment for an eating disorder * pregnant, nursing, or planned pregnancy in the next 6 months * planned weight loss surgery or procedure in the next 6 months * currently using medication for weight loss (prescribed or over the counter) * history of cardiovascular events * history of type 1 or type 2 diabetes * prescribed medication that might promote weight change such as lithium, steroids, or antipsychotics * medical contraindicate to weight loss (e.g., end-stage renal disease, cancer diagnosis with active/planned treatment) * psychiatric hospitalization in the past 12 months * investigator discretion for safety or to ensure appropriate treatment of study staff
microfragmented adipose tissue injection compared to hyaluronic acid for treatment of temporomandibular joint osteoarthritis

Conditions: Temporomandibular Joint Osteoarthritis

Summary: internal derangement and osteoarthritis are the most common degenerative temporomandibular joint diseases and initial treatment for such conditions relies on arthrocentesis. micro fragmentation of adipose tissue has been proven in orthopedic literature to represent a more effective method to preserve stem cells, but no application has ever been reported in the temporomandibular joint.

rationale for conducting the research: the rationale of this procedure is to remove inflammatory mediators, reduce friction, stimulate the production of new synovial fluid, eliminate suction-cup effect. the purpose of this study was to evaluate the hypothesis that tmj arthrocentesis with intraarticular injection of autologous micro fragmented adipose tissue leads to better clinical outcomes in terms of reducing pain and improving function compared with arthrocentesis and intraarticular injection of hyaluronic acid (ha) in patients with tmj internal derangement and osteoarthritis. preliminary results of this clinical trial show that the injection of micro fragmented adipose tissue can significantly improve outcomes of pain and function compared with the standard treatment and encourage to pursue research on this topic. further studies with a longer follow-up time are needed to evaluate the clinical stability of the achieved improvement in pain and function. for this reason, this protocol has been designed with the aim to investigate whether injection in the tmj of micro fragmented fat tissue can achieve the same improvements of pain and function, compare this technique with standard arthrocentesis with ha injection.

Eligibility criteria:
inclusion criteria: * \* tmj osteoarthritis assessed by clinical examination and mri imaging * presence of tmj-related symptoms including at least limited mouth opening and joint pain * previously failed conservative treatment * age superior to 14 years * no previous tmj surgical procedures * acquisition of informed consent; * complete availability of the data acquired preoperatively and during each follow-up * patients free from any systemic disease that may affect the procedure. exclusion criteria: * \* previously diagnosed hematological and neurological conditions; * previous malignant head and neck neoplasms; * contraindication to fat harvesting. * uncooperative patients.
intubation techniques on colonoscopy quality (sinocolo2013)

Conditions: Colorectal Adenoma; Colorectal Polyp

Summary: the primary aim of this study is - to explore the usefulness of abdominal compression on intubation. other aims include 1. to investigate the effectiveness and the efficacy of different manners of abdominal compression and to analysis the reasons of their success and failure 2. to get the knowledge of the formation of colon loops and its frequency 3. to clarify the impact of intubation with loops on adenoma detection rate


Eligibility criteria:
inclusion criteria: * patients who undergo colonoscopy examination for screening, surveillance, diagnosis or treatment exclusion criteria: * pregnant female patients * patients who have history of colorectal cancer, colorectal polyposis, inflammatory bowel disease or heredity colorectal neoplasm syndrome such as familiar adenomatous polyposis, lynch syndrome and so on * patients who had previous abdominal surgery * patients who are known to have colonic stricture or obstructing tumor from the results of radiography (x ray, ct scan or barium enema) * patients who are presenting acute surgical conditions such as severe colitis, megacolon and active gastrointestinal bleeding * patients who have inadequate bowel preparation * patients who reject to participate in this study

Keywords: colonoscopy lower gastrointestinal tract magnetic endoscopic imaging abdominal compression
assessment of somatic symptom in chinese community-dwelling people

Conditions: Somatization Disorder

Summary: with the rapid aging and worsening psychological problems worldwide, the special focus on somatic symptom and other psychological diseases of the older population is needed. however, there is no research comparing the incidence of somatic symptom between elderly and non-elderly, and clinical relevance with somatic symptom is uncertain. the study aims to clarify the prevalence of somatic symptom, depression and anxiety disorders in china, to compare physical and psychological difference between the elderly and non-elderly and to explore risk factors for somatic symptom in the elderly.

with the steadily increasing of life expectancy, the aging people is expected to 2 billion by 2050, which brings the deeper demand on the quality of life improvement. the psychological problems is an important factor affecting the quality of life. as reported, 73.6% of urban residents were with mental sub-health, indicating that psychological problem has grown into inevitable issues in hindering healthy development. the elderly, compared with the non-elderly, have unique social and biological characteristics, so psychological problem of the older population deserves special focus. literatures have investigated aged people with depression or anxiety disorder, but somatic symptom in elderly have rarely been addressed. somatic symptom disorder prevalence in elderly in european ranged from 0-13.5%. however, there is no research comparing the incidence of somatic symptom, anxiety and depression between elderly and non-elderly and revealing the prevalence of somatic symptom under diagnostic and statistical manual of mental disorders (dsm-5) criteria. investigators use somatic symptom scale-china (sss-cn) questionnaire to assess the presence and severity of the symptoms. patient heath questionnaire-9 (phq-9) and generalized anxiety disorder screener (gad-7) are used to evaluate depression and anxiety disorder respectively. the study aims to clarify the prevalence of somatic symptom, depression and anxiety disorders in china, to compare physical and psychological difference between the elderly and non-elderly and to explore risk factors for somatic symptom in the elderly.

Eligibility criteria:
inclusion criteria: 1. voluntary participants and gave written consent to participates the study; 2. undertook sss-cn questionnaire, phq-9 and gad questionnaires； exclusion criteria: 1. patients who have lost their self-assessed abilities or refuse to participate ; 2. patient with cancer and central nervous system disease; 3. patients who have been previously confirmed serious mental disorders, mental retardation or dementia.

Keywords: somatic symptom disorder somatic symptom scale-china elderly
impact of xenazine(tetrabenazine)on gait and functional activity in individuals with huntington's disease

Conditions: Huntington's Disease

Summary: in individuals with huntington's disease (hd), chorea may contribute to balance problems and difficulties with walking, sit to stand transfers and stair climbing that in turn may contribute to high fall rates. xenazine (tetrabenazine) is a monoamine-depleting drug that is commonly used to reduce chorea. the purpose of this study is to compare: 1) spatial and temporal gait measures, 2) performance on functional mobility measures, and 3) amount of daily walking activity before and after administration of xenazine in individuals with hd. it is hypothesized that the use of xenazine to decrease chorea will improve functions of 1) gait, 2) sit-to-stand transfers 3) stair climbing and 4) overall daily physical activity and function.

individuals with hd who are ambulatory and are either already taking xenazine or have been newly prescribed the medication will be recruited for this prospective open-label study. a variety of motor assessments will be preformed while subject are taking xenazine or after a period off of the medications. these tests include: unified huntington's disease rating scale (uhdrs) motor section, gaitrite forward walking, tinetti mobility test, timed sit-to-stand test, timed stair climb test, rhomberg test. a subset of subjects will wear an activity monitoring device on the wrist of the non-dominant hand for 5 consecutive days and nights.

Eligibility criteria:
inclusion criteria: * huntington's disease * able to ambulate independently exclusion criteria: * other orthopedic or neurological disorder that affects gait or balance * pregnancy * chorea score \<10 prior to initiation of medication. * inability to provide informed consent

Keywords: huntington's disease chorea gait balance